DOCSLIB.ORG

Ivashkiv 70 1..5

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Ivashkiv 70 1..5 Published: 14 September 2009 © 2009 Biology Reports Ltd Targeting cytokines in inflammatory diseases: focus on interleukin-1-mediated autoinflammation George D Kalliolias1 and Lionel B Ivashkiv1,2* Addresses: 1Arthritis and Tissue Degeneration Program and Department of Medicine, Hospital for Special Surgery, 535 East 70th Street, New York, NY 10021, USA; 2Graduate Program in Immunology and Microbial Pathogenesis, Weill Cornell Graduate School of Medical Sciences, 1300 York Avenue, New York, NY 10065, USA * Corresponding author: Lionel B Ivashkiv ([email protected]) F1000 Biology Reports 2009, 1:70 (doi:10.3410/B1-70) The electronic version of this article is the complete one and can be found at: http://F1000.com/Reports/Biology/content/1/70 Abstract In this commentary, we summarize the most recent advances in the cytokine-targeting therapies. We focus on new aspects of interleukin-1 (IL-1)-mediated autoinflammation and novel strategies to target IL-1. Introduction and context the IL-1 inhibitor anakinra appears to be only moder- The treatment of the broad and heterogeneous group ately effective in its FDA-approved indication for RA in of inflammatory diseases has been revolutionized with clinical practice [5]. the introduction of therapies that target cytokines [1]. Since 1998, the year that tumor necrosis factor-alpha Although anakinra did not fulfill all of the expectations (TNF-a) blockade was first approved for rheumatoid for managing RA, this therapeutic showed remarkable arthritis (RA), our cytokine-targeting armamentarium effectiveness in a heterogeneous group of heritable and has been enriched [1]. Table 1 summarizes all of the sporadic disorders now considered IL-1-mediated anti-cytokine regimens approved by the US Food and autoinflammatory diseases [10]. The prototype of Drug Administration (FDA), and Table 2 lists the these diseases is the cryopyrin-associated periodic cytokine-targeting therapies that are still under inves- syndrome (CAPS) [11]. CAPS is now considered a tigation [2]. Recent evidence suggests that interleukin-6 continuum of one disorder with varying severity and (IL-6) blockade using tocilizumab is effective in RA [3] includes the mild phenotype known as familial cold and that the p40 neutralizing antibody ustekinumab autoinflammatory syndrome (FCAS), the intermediate (targeting both IL-12 and IL-23) is beneficial for Muckle-Wells syndrome (MWS), and the severe form psoriasis [4]. of neonatal-onset multisystem inflammatory disorder (also called chronic infantile neurologic cutaneous and Despite all of these breakthroughs in targeting cyto- articular syndrome) [11]. kines, the treatment of inflammatory diseases is still imperfect and challenging. The high cost and the The immune system discriminates self from nonself and treatment-related adverse events (mainly infections distinguishes pathogens from commensal organisms and and the reported, but controversial, increased risk for specifically eliminates pathogens. Regulation of immune malignancies) are major drawbacks of cytokine target- responses restrains concurrent tissue damage and ing [5-7]. In addition, the available cytokine blockade is orchestrates tissue repair. This balance between defense not always effective, as exemplified by the failure of the and protection of tissue integrity results from a tight anti-p40 monoclonal antibody to show a significant regulation of the innate and adaptive branches of benefit in patients with multiple sclerosis [8]. Further- the immune system. Failure of these regulatory mecha- more, approximately 30% of RA patients do not nisms causes an aberrant immune response ranging respond adequately to anti-TNF-a treatments [9] and from inadequate defense to uncontrolled/unprovoked Page 1 of 5 (page number not for citation purposes) F1000 Biology Reports 2009, 1:70 http://F1000.com/Reports/Biology/content/1/70 Table 1. Cytokine-targeting therapies approved by the US Food of autoantibodies [11,13,14]. To distinguish this group and Drug Administration for the treatment of inflammatory of diseases from autoimmune diseases, emphasizing the diseases primary role of innate immunity in driving their Targeted cytokine Description FDA-approved ‘ ’ indications pathogenesis, the term autoinflammatory diseases has been proposed [11,13,14]. The new aspects in the a TNF- concept of IL-1-mediated autoinflammation and the 1. Etanercept (Enbrel®; Dimeric fusion protein • RA Amgen, Thousand Oaks, consisting of the • JIA recent advances in targeting IL-1 will be the focus of this CA, USA, and Wyeth, ligand-binding portion of • ASp commentary. Madison, NJ, USA) human p75TNFR linked • Psoriasis to the Fc of human IgG1 • PsA 2. Infliximab Chimeric (human and • RA Major recent advances (Remicade®; Johnson & mouse) IgG1k • ASp Understanding Horror autoinflammaticus a • Johnson, New anti-TNF- Mab Psoriasis More than 60 mutations in the CIAS1 gene are responsible Brunswick, NJ, USA) • PsA • CD for a hyperactive NALP3 (cryopyrin) leading to CAPS [11]. • UC NALP3 functions as a sensor of pathogens and danger • 3. Adalimumab Recombinant human IgG1 RA signals and is expressed mainly in immune cells, (Humira®; Abbott anti-TNF-a Mab • JIA Laboratories, Abbott • ASp chondrocytes, and epithelial cells [15]. Upon activation, Park, IL, USA) • Psoriasis NALP3 recruits ASC (apoptosis-associated speck-like • PsA protein containing caspase-recruitment domain), Cardi- • CD 4. Certolizumab pegol Humanized Fab fragment • RA nal, and pro-caspase-1, assembling a multimeric complex (Cimzia®; UCB, of anti-TNF-a Mab • CD called the inflammasome. NALP3 inflammasomes acti- Brussels, Beglium) conjugated to PEG vate the downstream caspase-1, the protease that cleaves 5. Golimumab Human IgG1k • RA pro-IL-1, releasing the potent pyrogen IL-1b [15,16]. The (Simponi™; Centocor anti-TNF-a Mab • ASp understanding of the direct role of NALP3 in IL-1b • Ortho Biotech, Inc., PsA processing led to the concept that CAPS (a result of Horsham, PA, USA) hyperactive inflammasome due to mutated NALP3) is an IL-1 IL-1-mediated autoinflammatory disease, justifying the 1. Anakinra (Kineret®; Recombinant human • RA Amgen) IL-1Ra that inhibits IL-1 by use of IL-1 blockade to control disease activity [11]. binding IL-1RI 2. Rilonacept Consisting of the • CAPS Targeting IL-1b to treat autoinflammation (Arcalyst™; Regeneron ligand-binding domains of Pharmaceuticals, Inc, human IL-1RI and IL-1AcP The recombinant human IL-1 receptor antagonist ana- Tarrytown, NY, USA) fused in line with Fc of kinra was the first IL-1-targeting intervention used in human IgG1 (IL-1 trap) patients with CAPS with impressive effectiveness ASp, ankylosing spondylitis; CAPS, cryopyrin-associated periodic [17-19]. The short half-life of anakinra necessitates syndrome; CD, Crohn' s disease; Fab, fragment antigen-binding; FDA, US daily injections for efficient responses, and injection Food and Drug Administration; IgG, immunoglobulin G; IL-1, interleukin-1; site reactions are commonly observed [5,17-19]. To IL-1AcP, interleukin-1 accessory protein; IL-1Ra, interleukin-1 receptor overcome these limitations, sophisticated investigation antagonist; JIA, juvenile idiopathic arthritis; Mab, monoclonal antibody; resulted in new efficient strategies to target IL-1 with PEG, polyethylene glycol; PsA, psoriatic arthritis; RA, rheumatoid arthritis; improved pharmacokinetics and thus better compliance TNF-a, tumor necrosis factor-alpha; TNFR, tumor necrosis factor and tolerance [20,21]. receptor; UC, ulcerative colitis. Rilonacept is a new IL-1 blocker that functions as an inflammation. Generation of pathogenic autoantibodies IL-1 trap, binding IL-1 with an affinity at least 100-fold or autoreactive T-cell clones or both, due to deregulated higher than that of the native IL-1 cell surface receptor adaptive immunity, leads to ‘autoimmunity’ [12]. complex [22]. Normally, IL-1b binds first to IL-1RI on Systemic lupus erythematosus exemplifies systemic the surface of target cells and subsequently IL-1 autoimmunity, whereas autoimmune thyroiditis and accessory protein (IL-1AcP) is recruited, thus forming diabetes mellitus type I reflect some facets of tissue- a trimolecular signaling complex [16]. Rilonacept is an specific autoimmunity [12]. artificial molecule that contains the ligand-binding portions of both IL-1RI and IL-1AcP fused to a dimeric Now it is well established that genetic defects in molecule containing the Fc segment of hIgG1 (human molecules regulating the function of the innate immune immunoglobulin G1) [22]. In contrast to the system are the cause of several diseases characterized by daily injected anakinra, rilonacept has a half-life of systemic or localized inflammation in the absence of approximately 7 days and thus is administered once infection, autoreactive lymphocytes, and high titers weekly [20]. Page 2 of 5 (page number not for citation purposes) F1000 Biology Reports 2009, 1:70 http://F1000.com/Reports/Biology/content/1/70 Table 2. Cytokine-targeting therapies that are under investigation in clinical trials Targeted cytokine Description Investigational trials IL-1 Rilonacept IL-1 trap (Table 1) FMF/AOSD/SoJIA/Gout Canakinumab Anti-IL-1 Mab CAPS/SoJIA/RA/Gout/DM II/COPD IL-4 and IL-13 Pascolizumab Anti-IL-4 Mab Asthma Pitrakinra (blocks IL-4 and IL-13) Mutated IL-4 Asthma CAT-354, IMA-638, QAX576 Anti-IL-13 Mabs Asthma/IPF/Allergic rhinitis/SSc IL-5 Mepolizumab Anti-IL-5 Mab Asthma/CSS/HES MEDI-563 Anti-IL-5R Mab Asthma IL-6 Tocilizumab Anti-IL-6R Mab RA/SoJIA IL-9 MEDI-528 Anti-IL-9 Mab Asthma p40 (IL-12 and IL-23) Ustekinumab (CNTO 1275) hIgG1 anti-p40 Mab Psoriasis/PsA/CD ABT-874/J695 hIgG1l anti-p40 Mab Psoriasis/CD IL-15 HuMax-IL-15 (AMG 714) Anti-IL-15 Mab RA/Psoriasis IL-17A AIN457 Anti-IL-17A Mab RA/Psoriasis/PsA/ASp/CD/Uveitis IL-23 Anti-p19 Mab Clinical trials in preliminary stage. No further information available. TGF-b CAT-192 Anti-TGF-beta1 Mab SSc TNF superfamily 1. BAFF(BLyS)/APRIL Atacicept (blocks BLyS and APRIL) Ligand-binding portion of TACI fused with hIgG1 Fc SLE/RA/MS/Optic neuritis Belimumab Anti-BLyS Mab SLE/RA 2. LTa1b2 and LIGHT Baminercept Ligand-binding portion of LT-b R fused with hIgG1 Fc RA 3.
Load more

Recommended publications
  • Pharmacologic Considerations in the Disposition of Antibodies and Antibody-Drug Conjugates in Preclinical Models and in Patients
    antibodies Review Pharmacologic Considerations in the Disposition of Antibodies and Antibody-Drug Conjugates in Preclinical Models and in Patients Andrew T. Lucas 1,2,3,*, Ryan Robinson 3, Allison N. Schorzman 2, Joseph A. Piscitelli 1, Juan F. Razo 1 and William C. Zamboni 1,2,3 1 University of North Carolina (UNC), Eshelman School of Pharmacy, Chapel Hill, NC 27599, USA; [email protected] (J.A.P.); [email protected] (J.F.R.); [email protected] (W.C.Z.) 2 Division of Pharmacotherapy and Experimental Therapeutics, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA; [email protected] 3 Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA; [email protected] * Correspondence: [email protected]; Tel.: +1-919-966-5242; Fax: +1-919-966-5863 Received: 30 November 2018; Accepted: 22 December 2018; Published: 1 January 2019 Abstract: The rapid advancement in the development of therapeutic proteins, including monoclonal antibodies (mAbs) and antibody-drug conjugates (ADCs), has created a novel mechanism to selectively deliver highly potent cytotoxic agents in the treatment of cancer. These agents provide numerous benefits compared to traditional small molecule drugs, though their clinical use still requires optimization. The pharmacology of mAbs/ADCs is complex and because ADCs are comprised of multiple components, individual agent characteristics and patient variables can affect their disposition. To further improve the clinical use and rational development of these agents, it is imperative to comprehend the complex mechanisms employed by antibody-based agents in traversing numerous biological barriers and how agent/patient factors affect tumor delivery, toxicities, efficacy, and ultimately, biodistribution.
    [Show full text]
  • Cytokine Nomenclature
    RayBiotech, Inc. The protein array pioneer company Cytokine Nomenclature Cytokine Name Official Full Name Genbank Related Names Symbol 4-1BB TNFRSF Tumor necrosis factor NP_001552 CD137, ILA, 4-1BB ligand receptor 9 receptor superfamily .2. member 9 6Ckine CCL21 6-Cysteine Chemokine NM_002989 Small-inducible cytokine A21, Beta chemokine exodus-2, Secondary lymphoid-tissue chemokine, SLC, SCYA21 ACE ACE Angiotensin-converting NP_000780 CD143, DCP, DCP1 enzyme .1. NP_690043 .1. ACE-2 ACE2 Angiotensin-converting NP_068576 ACE-related carboxypeptidase, enzyme 2 .1 Angiotensin-converting enzyme homolog ACTH ACTH Adrenocorticotropic NP_000930 POMC, Pro-opiomelanocortin, hormone .1. Corticotropin-lipotropin, NPP, NP_001030 Melanotropin gamma, Gamma- 333.1 MSH, Potential peptide, Corticotropin, Melanotropin alpha, Alpha-MSH, Corticotropin-like intermediary peptide, CLIP, Lipotropin beta, Beta-LPH, Lipotropin gamma, Gamma-LPH, Melanotropin beta, Beta-MSH, Beta-endorphin, Met-enkephalin ACTHR ACTHR Adrenocorticotropic NP_000520 Melanocortin receptor 2, MC2-R hormone receptor .1 Activin A INHBA Activin A NM_002192 Activin beta-A chain, Erythroid differentiation protein, EDF, INHBA Activin B INHBB Activin B NM_002193 Inhibin beta B chain, Activin beta-B chain Activin C INHBC Activin C NM005538 Inhibin, beta C Activin RIA ACVR1 Activin receptor type-1 NM_001105 Activin receptor type I, ACTR-I, Serine/threonine-protein kinase receptor R1, SKR1, Activin receptor-like kinase 2, ALK-2, TGF-B superfamily receptor type I, TSR-I, ACVRLK2 Activin RIB ACVR1B
    [Show full text]
  • Kate Fitzgerald
    In This Issue: 2020 Young Investigator Awardees pg. 3-9 In Memorium page pg. 14-15 New Member Mini-Bios pg. 19-21 Trials of Interferon Lambda pg. 31 Cytokines 2021 Hybrid Meetin pg. 24-27 Signals THE INTERNATIONAL CYTOKINE & INTERFERON SOCIETY + NEWSLETTER APRIL 2021 I VOLUME 9 I NO. 1 A NOTE FROM THE ICIS PRESIDENT Kate Fitzgerald Dear Colleagues, Greetings from the International Cytokine and Interferon Society! I hope you and your family are staying safe during these still challenging times. Thankfully 2020 is behind us now. We have lived through the COVID-19 pandemic, an event that will continue to impact our lives for some time and likely alter how we live in the future. Despite the obvious difficulties of this past year, I can’t help but marvel at the scientific advances that have been made. With everything from COVID-19 testing, to treatments and especially to the rapid pace of vaccine development, we are so better off today than even a few months back. The approval of remarkably effective COVID-19 vaccines now rolling out in the US, Israel, UK, Europe and across the globe, brings light at the end of the tunnel. The work of many of you has helped shape our understanding of the host response to Sars-CoV2 and the ability of this virus to limit antiviral immunity while simultaneously driving a cytokine driven hyperinflammatory response leading to deadly consequences for patients. The knowledge gained from all of your efforts has been put to good use to stem the threat of this deadly virus.
    [Show full text]
  • Interleukins in Therapeutics
    67 ISSN: 2347 - 7881 Review Article Interleukins in Therapeutics Anjan Khadka Department of Pharmacology, AFMC, Pune, India [email protected] ABSTRACT Interleukins are a subset of a larger group of cellular messenger molecules called cytokines, which are modulators of cellular behaviour. On the basis of their respective cytokine profiles, responses to chemokines, and interactions with other cells, these T-cell subsets can promote different types of inflammatory responses. During the development of allergic disease, effector TH2 cells produce IL-4, IL- 5, IL-9, and IL-32. IL-25, IL- 31, and IL-33 contributes to TH2 responses and inflammation. These cytokines have roles in production of allergen-specific IgE, eosinophilia, and mucus. ILs have role in therapeutics as well as diagnosis and prognosis as biomarker in various conditions. Therapeutic targeting of the IL considered to be rational treatment strategy and promising biologic therapy. Keywords: Interleukins, cytokines, Interleukin Inhibitors, Advances INTRODUCTION meaning ‘hormones’. It was Stanley Cohen in Interleukins are group of cytokines that were 1974 who for the first time introduced the term first seen to be expressed by leucocytes and ‘‘cytokine’’. It includes lymphokines, they interact between cells of the immune monokines, interleukins, and colony stimulating systems. It is termed by Dr. Vern Paetkau factors (CSFs), interferons (IFNs), tumor (University of Victoria) in1979.Interleukins (IL) necrosis factor (TNF) and chemokines. The are able to promote cell growth, differentiation, majority of interleukins are synthesized by and functional activation. The question of how helper CD4 T lymphocytes as well as through diverse cell types communicate with each monocytes, macrophages, and endothelial cells.
    [Show full text]
  • Review Anti-Cytokine Biologic Treatment Beyond Anti-TNF in Behçet's Disease
    Review Anti-cytokine biologic treatment beyond anti-TNF in Behçet’s disease A. Arida, P.P. Sfikakis First Department of Propedeutic Internal ABSTRACT and thrombotic complications (1-3). Medicine Laikon Hospital, Athens, Unmet therapeutic needs in Behçet’s Treatment varies according to type and University Medical School, Greece. disease have drawn recent attention to severity of disease manifestations. Cor- Aikaterini Arida, MD biological agents targeting cytokines ticosteroids, interferon-alpha and con- Petros P. Sfikakis, MD other than TNF. The anti-IL-17 anti- ventional immunosuppressive drugs, Please address correspondence to: body secukinumab and the anti-IL-2 such as azathioprine, cyclosporine-A, Petros P. Sfikakis, MD, receptor antibody daclizumab were not cyclophosphamide and methotrexate, First Department of Propedeutic superior to placebo for ocular Behçet’s and Internal Medicine, are used either alone or in combination Laikon Hospital, in randomised controlled trials, com- for vital organ involvement. During the Athens University Medical School, prising 118 and 17 patients, respec- last decade there has been increased use Ag Thoma, 17, tively. The anti-IL-1 agents anakinra of anti-TNF monoclonal antibodies in GR-11527 Athens, Greece. and canakinumab and the anti-IL-6 patients with BD who were refractory E-mail: [email protected] agent tocilizumab were given to iso- to conventional treatment or developed Received on June 7, 2014; accepted in lated refractory disease patients, who life-threatening complications (4, 5). revised form on September 17, 2014. were either anti-TNF naïve (n=9) or Anti-TNF treatment has been shown to Clin Exp Rheumatol 2014; 32 (Suppl. 84): experienced (n=18).
    [Show full text]
  • Biological Therapies for Atopic Dermatitis: an Update (Review)
    EXPERIMENTAL AND THERAPEUTIC MEDICINE 17: 1061-1067, 2019 Biological therapies for atopic dermatitis: An update (Review) DIANA DELEANU1-3 and IRENA NEDELEA1,2 1Allergology and Immunology Discipline, ‘Iuliu Hatieganu’ University of Medicine and Pharmacy, 400058 Cluj-Napoca; Departments of 2Allergy and 3Internal Medicine, ‘Professor Doctor Octavian Fodor’ Regional Institute of Gastroenterology and Hepatology, 400162 Cluj-Napoca, Romania Received July 6, 2018; Accepted August 22, 2018 DOI: 10.3892/etm.2018.6989 Abstract. Severe atopic dermatitis, which affects both adults in low-income countries (3). Furthermore, the past decades and children, is a debilitating disorder with a significant decline brought a 2-3-fold increase in prevalence in industrialized of patients' quality of life. Although aetiopathogenic factors countries (3). Generally AD onset is in early childhood, as are currently a topic of study and interpretation, the main one of the first steps of the ‘atopic march’, which describes the features of atopic eczema are skin barrier disturbance and natural history of atopic manifestations, and it is character- immune dysregulation. Severe refractory disease that fails to ized by xerotic skin and acute flare-ups of intensely pruritic improve with conventional therapy may benefit from biologic eczematous lesions (4). Recent studies recognize a predilection therapy. Progress in understanding immunopathology of atopic of AD for persistence in adulthood, with a lifetime prevalence dermatitis have allowed identification of therapeutic molecular accounting for 34.1% (5). Early onset, allergic rhinitis and targets in the field of biological therapy. We reviewed the hand eczema in childhood are high-risk factors for persistent different biological treatments with a focus on novel targeted AD (5).
    [Show full text]
  • Anticorps FR-EN 110X90.Indd
    MONOCLONAL ANTIBODIES and Fc fusion proteins for therapeutic use DISTRIBUTION OF INTERNATIONAL NONPROPRIETARY NAMES BY INDICATION SOLID TUMORS RHUMATOLOGY PNEUMOLOGY Lung cancer bevacizumab Rheumatoid arthritis etanercept Allergic asthma omalizumab nivolumab infliximab Severe eosinophilic asthma mepolizumab necitumumab adalimumab reslizumab atezolizumab rituximab Colorectal cancer bevacizumab abatacept TRANSPLANTATION cetuximab tocilizumab Transplant rejection basiliximab panitumumab certolizumab pegol belatacept aflibercept golimumab Graft versus host disease inolimomab Bladder cancer atezolizumab Psoriatic arthritis etanercept Breast cancer trastuzumab adalimumab OPHTALMOLOGY bevacizumab infliximab Age related macular ranibizumab pertuzumab golimumab degeneration aflibercept trastuzumab entansine ustekinumab bevacizumab Gastric cancer trastuzumab certolizumab pegol Macular edema ranibizumab ramucirumab secukinumab aflibercept Head and neck cancer cetuximab Ankylosing spondylitis infliximab Myopic choroidal ranibizumab Ovarian cancer bevacizumab etanercept neovascularization aflibercept Fallopian tube cancer bevacizumab adalimumab Cervical cancer bevacizumab golimumab HAEMOSTASIS AND THROMBOSIS Kidney cancer bevacizumab certolizumab pegol nivolumab secukinumab Haemophilia A efmoroctocog α Melanoma ipilimumab Juvenile arthritis etanercept Haemophilia B eftrenonacog α nivolumab adalimumab Reversal of dabigatran idarucizumab Idiopathic thrombocytopenic pembrolizumab abatacept romiplostim Neuroblastoma dinutuximab tocilizumab purpura Malignant
    [Show full text]
  • Pulmonary Delivery of Biological Drugs
    pharmaceutics Review Pulmonary Delivery of Biological Drugs Wanling Liang 1,*, Harry W. Pan 1 , Driton Vllasaliu 2 and Jenny K. W. Lam 1 1 Department of Pharmacology and Pharmacy, Li Ka Shing Faculty of Medicine, The University of Hong Kong, 21 Sassoon Road, Pokfulam, Hong Kong, China; [email protected] (H.W.P.); [email protected] (J.K.W.L.) 2 School of Cancer and Pharmaceutical Sciences, King’s College London, 150 Stamford Street, London SE1 9NH, UK; [email protected] * Correspondence: [email protected]; Tel.: +852-3917-9024 Received: 15 September 2020; Accepted: 20 October 2020; Published: 26 October 2020 Abstract: In the last decade, biological drugs have rapidly proliferated and have now become an important therapeutic modality. This is because of their high potency, high specificity and desirable safety profile. The majority of biological drugs are peptide- and protein-based therapeutics with poor oral bioavailability. They are normally administered by parenteral injection (with a very few exceptions). Pulmonary delivery is an attractive non-invasive alternative route of administration for local and systemic delivery of biologics with immense potential to treat various diseases, including diabetes, cystic fibrosis, respiratory viral infection and asthma, etc. The massive surface area and extensive vascularisation in the lungs enable rapid absorption and fast onset of action. Despite the benefits of pulmonary delivery, development of inhalable biological drug is a challenging task. There are various anatomical, physiological and immunological barriers that affect the therapeutic efficacy of inhaled formulations. This review assesses the characteristics of biological drugs and the barriers to pulmonary drug delivery.
    [Show full text]
  • Modifications to the Harmonized Tariff Schedule of the United States To
    U.S. International Trade Commission COMMISSIONERS Shara L. Aranoff, Chairman Daniel R. Pearson, Vice Chairman Deanna Tanner Okun Charlotte R. Lane Irving A. Williamson Dean A. Pinkert Address all communications to Secretary to the Commission United States International Trade Commission Washington, DC 20436 U.S. International Trade Commission Washington, DC 20436 www.usitc.gov Modifications to the Harmonized Tariff Schedule of the United States to Implement the Dominican Republic- Central America-United States Free Trade Agreement With Respect to Costa Rica Publication 4038 December 2008 (This page is intentionally blank) Pursuant to the letter of request from the United States Trade Representative of December 18, 2008, set forth in the Appendix hereto, and pursuant to section 1207(a) of the Omnibus Trade and Competitiveness Act, the Commission is publishing the following modifications to the Harmonized Tariff Schedule of the United States (HTS) to implement the Dominican Republic- Central America-United States Free Trade Agreement, as approved in the Dominican Republic-Central America- United States Free Trade Agreement Implementation Act, with respect to Costa Rica. (This page is intentionally blank) Annex I Effective with respect to goods that are entered, or withdrawn from warehouse for consumption, on or after January 1, 2009, the Harmonized Tariff Schedule of the United States (HTS) is modified as provided herein, with bracketed matter included to assist in the understanding of proclaimed modifications. The following supersedes matter now in the HTS. (1). General note 4 is modified as follows: (a). by deleting from subdivision (a) the following country from the enumeration of independent beneficiary developing countries: Costa Rica (b).
    [Show full text]
  • Asthma Agents
    APPROVED PA Criteria Initial Approval Date: July 10, 2019 Revised Date: January 20, 2021 CRITERIA FOR PRIOR AUTHORIZATION Asthma Agents BILLING CODE TYPE For drug coverage and provider type information, see the KMAP Reference Codes webpage. MANUAL GUIDELINES Prior authorization will be required for all current and future dose forms available. All medication-specific criteria, including drug-specific indication, age, and dose for each agent is defined in Table 1 below. Benralizumab (Fasenra®) Dupilumab (Dupixent®) Mepolizumab (Nucala®) Omalizumab (Xolair®) Reslizumab (Cinqair®) GENERAL CRITERIA FOR INITIAL PRIOR AUTHORIZATION: (must meet all of the following) • Must be approved for the indication, age, and not exceed dosing limits listed in Table 1. • Must be prescribed by or in consultation with a pulmonologist, allergist, or immunologist.1,2 • For all agents listed, the preferred PDL drug, which treats the PA indication, is required unless the patient meets the non-preferred PDL PA criteria. • Must have experienced ≥ 2 exacerbations within the last 12 months despite meeting all of the following (exacerbation is defined as requiring the use of oral/systemic corticosteroids, urgent care/hospital admission, or intubation: o Patient adherence to two long-term controller medications, including a high-dose inhaled corticosteroid 1,2 (ICS) and a long-acting beta2-agonist (LABA) listed in Table 2. ▪ Combination ICS/LABA and ICS/LABA/LAMA products meet the requirement of two controller medications. o Patient must have had an adequate trial (at least 90 consecutive days) of a leukotriene modifier or a long-acting muscarinic antagonist (LAMA) as a third long-term controller medication listed in Table 2.
    [Show full text]
  • Cimzia (Certolizumab Pegol) AHM
    Cimzia (Certolizumab Pegol) AHM Clinical Indications • Cimzia (Certolizumab Pegol) is considered medically necessary for adult members 18 years of age or older with moderately-to-severely active disease when ALL of the following conditions are met o Moderately-to-severely active Crohn's disease as manifested by 1 or more of the following . Diarrhea . Abdominal pain . Bleeding . Weight loss . Perianal disease . Internal fistulae . Intestinal obstruction . Megacolon . Extra-intestinal manifestations: arthritis or spondylitis o Crohn's disease has remained active despite treatment with 1 or more of the following . Corticosteroids . 6-mercaptopurine/azathioprine • Certollizumab pegol (see note) is considered medically necessary for persons with active psoriatic arthritis who meet criteria in Psoriasis and Psoriatic Arthritis: Biological Therapies. • Cimzia, (Certolizumab Pegol), alone or in combination with methotrexate (MTX), is considered medically necessary for the treatment of adult members 18 years of age or older with moderately-to-severely active rheumatoid arthritis (RA). • Cimzia (Certolizumab pegol is considered medically necessary for reducing signs and symptoms of members with active ankylosing spondylitis who have an inadequate response to 2 or more NSAIDs. • Cimzia (Certolizumab Pegol) is considered investigational for all other indications (e.g.,ocular inflammation/uveitis; not an all-inclusive list) because its effectiveness for indications other than the ones listed above has not been established. Notes • There are several brands of targeted immune modulators on the market. There is a lack of reliable evidence that any one brand of targeted immune modulator is superior to other brands for medically necessary indications. Enbrel (etanercept), Humira (adalimumab), Remicade (infliximab), Simponi (golimumab), Simponi Aria (golimumab intravneous), and Stelara (ustekinumab) brands of targeted immune modulators ("least cost brands of targeted immune modulators") are less costly to the plan.
    [Show full text]
  • The Two Tontti Tudiul Lui Hi Ha Unit
    THETWO TONTTI USTUDIUL 20170267753A1 LUI HI HA UNIT ( 19) United States (12 ) Patent Application Publication (10 ) Pub. No. : US 2017 /0267753 A1 Ehrenpreis (43 ) Pub . Date : Sep . 21 , 2017 ( 54 ) COMBINATION THERAPY FOR (52 ) U .S . CI. CO - ADMINISTRATION OF MONOCLONAL CPC .. .. CO7K 16 / 241 ( 2013 .01 ) ; A61K 39 / 3955 ANTIBODIES ( 2013 .01 ) ; A61K 31 /4706 ( 2013 .01 ) ; A61K 31 / 165 ( 2013 .01 ) ; CO7K 2317 /21 (2013 . 01 ) ; (71 ) Applicant: Eli D Ehrenpreis , Skokie , IL (US ) CO7K 2317/ 24 ( 2013. 01 ) ; A61K 2039/ 505 ( 2013 .01 ) (72 ) Inventor : Eli D Ehrenpreis, Skokie , IL (US ) (57 ) ABSTRACT Disclosed are methods for enhancing the efficacy of mono (21 ) Appl. No. : 15 /605 ,212 clonal antibody therapy , which entails co - administering a therapeutic monoclonal antibody , or a functional fragment (22 ) Filed : May 25 , 2017 thereof, and an effective amount of colchicine or hydroxy chloroquine , or a combination thereof, to a patient in need Related U . S . Application Data thereof . Also disclosed are methods of prolonging or increasing the time a monoclonal antibody remains in the (63 ) Continuation - in - part of application No . 14 / 947 , 193 , circulation of a patient, which entails co - administering a filed on Nov. 20 , 2015 . therapeutic monoclonal antibody , or a functional fragment ( 60 ) Provisional application No . 62/ 082, 682 , filed on Nov . of the monoclonal antibody , and an effective amount of 21 , 2014 . colchicine or hydroxychloroquine , or a combination thereof, to a patient in need thereof, wherein the time themonoclonal antibody remains in the circulation ( e . g . , blood serum ) of the Publication Classification patient is increased relative to the same regimen of admin (51 ) Int .
    [Show full text]